These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34129705)

  • 1. Risks and mitigation strategies to prevent etoposide infusion-related reactions in children.
    Tillman EM; Suppes SL; Miles N; Duty AM; Kelley KL; Goldman JL
    Pharmacotherapy; 2021 Aug; 41(8):700-706. PubMed ID: 34129705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between in-line filtration and Type I hypersensitivity reactions in pediatric oncology patients receiving intravenous etoposide.
    Ronsley R; Jacques L; Potts JE; Clement K; Dix DB; Mahon P
    Pediatr Hematol Oncol; 2021 Apr; 38(3):208-215. PubMed ID: 33150845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous Flare Reactions: A Case Report of Reactions Following Etoposide Infusion.
    Mini Gill J; Frost J; Park R; Saria MG
    Clin J Oncol Nurs; 2018 Dec; 22(6):597-599. PubMed ID: 30452012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute infusion-related reactions in pediatric patients receiving etoposide at a tertiary cancer center.
    McBride P; Degar B
    J Oncol Pharm Pract; 2024 Jan; 30(1):197-200. PubMed ID: 37960879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide and etoposide phosphate hypersensitivity in children: Incidence, risk factors, and prevention strategies.
    Stockton WM; Nguyen T; Zhang L; Dowling TC
    J Oncol Pharm Pract; 2020 Mar; 26(2):397-405. PubMed ID: 31315549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease.
    Hudson MM; Weinstein HJ; Donaldson SS; Greenwald C; Kun L; Tarbell NJ; Humphrey WA; Rupp C; Marina NM; Wilimas J
    J Clin Oncol; 1993 Jun; 11(6):1080-4. PubMed ID: 8501494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.
    Roselló S; Blasco I; García Fabregat L; Cervantes A; Jordan K;
    Ann Oncol; 2017 Jul; 28(suppl_4):iv100-iv118. PubMed ID: 28881914
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5.
    Fields SZ; Igwemezie LN; Kaul S; Schacter LP; Schilder RJ; Litam PP; Himpler BS; McAleer C; Wright J; Barbhaiya RH
    Clin Cancer Res; 1995 Jan; 1(1):105-11. PubMed ID: 9815892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypersensitivity to carboplatin in children.
    Schiavetti A; Varrasso G; Maurizi P; Castello MA
    Med Pediatr Oncol; 1999 Mar; 32(3):183-5. PubMed ID: 10064185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity.
    Collier K; Schink C; Young AM; How K; Seckl M; Savage P
    J Oncol Pharm Pract; 2008 Mar; 14(1):51-5. PubMed ID: 18337441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypersensitivity reactions to etoposide phosphate.
    Sambasivan K; Mahmoud S; Kokache A; Seckl M; Savage P
    J Oncol Pharm Pract; 2014 Apr; 20(2):158-60. PubMed ID: 23740378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab infusion reactions: French pharmacovigilance database analysis.
    Grandvuillemin A; Disson-Dautriche A; Miremont-Salamé G; Fourrier-Reglat A; Sgro C;
    J Oncol Pharm Pract; 2013 Jun; 19(2):130-7. PubMed ID: 23154574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoposide hypersensitivity reactions associated with in-line filter use: A retrospective cohort study at CHU de Québec-Université Laval.
    Dodier K; Laverdière I; Roy MJ
    J Oncol Pharm Pract; 2023 Oct; 29(7):1687-1694. PubMed ID: 36544381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidisciplinary Approach to Deciphering Etoposide Infusion Reactions and Potential Role of Polyethersulfone Filter Membranes.
    Miles N; Masters A; Desta Z; Goldman JL; Suppes SL; Tillman EM
    J Pediatr Pharmacol Ther; 2023; 28(7):643-648. PubMed ID: 38025152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Infusion-Related Reactions: How to Recognize and Intervene When These Reactions Occur in Practice.
    Price M
    Clin J Oncol Nurs; 2021 Oct; 25(5):591-594. PubMed ID: 34533514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
    Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
    Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population.
    Rozette NA; Hellauer CM; McKee C; Vazifedan T; Gabriel CA; Dice JE; Yokois NU
    Inflamm Bowel Dis; 2018 Aug; 24(9):2007-2014. PubMed ID: 29788416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.